Google
GLPG — GALAPAGOS NV ADR (Healthcare >> Biotechnology)
GLPG FAQ
What is GLPG's P/E ratio?
GALAPAGOS NV ADR (GLPG) currently trades at a P/E ratio of 2.34.
What is GLPG's ROE?
GALAPAGOS NV ADR reports a Return on Equity (ROE) of 15.02%.
What is GLPG's dividend yield?
GALAPAGOS NV ADR offers a dividend yield of 0.00%.
What is GLPG's Deepscope Quality Score?
Deepscope rates GLPG's overall financial quality at 85 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy GLPG?
Deepscope's AI Timing Score for GLPG is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does GLPG belong to?
GALAPAGOS NV ADR is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 28.02
Price
-0.29
(-1.02%)
Day Change
|
|
|---|
GLPG, the overall quality is very good ( Quality = 85) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
Historical ROE is relatively low
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are ok , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
63% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
169
|
| Magic Formula Rank by ROE |
169
|
| Magic Formula Rank by ROIC |
56
GOOD
|
| Price | 28.02 |
| PBV / Sector |
0.57 / 4.63
GREAT
|
| Earning Per Share | 7.35 |
| PE / Sector |
2.34 / 17.43
GREAT
|
| PEG or PE/Growth / Sector |
0.10 / 0.53
GREAT
|
| Average 1M Daily Value |
4.78 M
GREAT
|
| Average 1W Daily Value |
3.24 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
68% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:45 |
| Symbol | GLPG |
| Name | GALAPAGOS NV ADR |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 65.90 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,862.33 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800
Phone: 32 1 534 29 00
Website: https://www.glpg.com
Employees: 704
Sector: Healthcare >> Biotechnology
Description: Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
